Published in J Neural Transm (Vienna) on December 16, 2005
Neuropsychological outcomes from constant current deep brain stimulation for Parkinson's disease. Mov Disord (2016) 2.68
CBT for the treatment of depression in Parkinson's disease: a promising nonpharmacological approach. Expert Rev Neurother (2008) 0.99
Long-term effects of STN DBS on mood: psychosocial profiles remain stable in a 3-year follow-up. BMC Neurol (2008) 0.86
Neuropsychiatric symptoms three years after subthalamic DBS in PD patients: a case-control study. J Neurol (2008) 0.84
Comparison of frequencies of non motor symptoms in Indian Parkinson's disease patients on medical management versus deep brain stimulation: A case-control study. Iran J Neurol (2015) 0.76
Neurosurgery in Parkinson's disease: Social adjustment, quality of life and coping strategies. Neural Regen Res (2013) 0.76
Older Candidates for Subthalamic Deep Brain Stimulation in Parkinson's Disease Have a Higher Incidence of Psychiatric Serious Adverse Events. Front Aging Neurosci (2016) 0.75
The assessment of anxiety states by rating. Br J Med Psychol (1959) 24.58
Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci (1986) 18.17
Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med (2003) 6.59
Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res (1990) 5.79
Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med (1999) 4.79
Clinical applications of visual analogue scales: a critical review. Psychol Med (1988) 4.69
Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry (2002) 3.41
Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord (1999) 2.98
Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. Brain (2000) 2.25
Long term effects of bilateral subthalamic nucleus stimulation on cognitive function, mood, and behaviour in Parkinson's disease. J Neurol Neurosurg Psychiatry (2004) 2.21
Effects of bilateral subthalamic stimulation on cognitive function in Parkinson disease. Arch Neurol (2001) 2.06
Neuropsychological changes between "off" and "on" STN or GPi stimulation in Parkinson's disease. Neurology (2000) 1.85
Mania following deep brain stimulation for Parkinson's disease. Neurology (2002) 1.64
Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study. Neurosurgery (1999) 1.63
Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology (2001) 1.61
Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. Mov Disord (2003) 1.58
Bilateral subthalamic or pallidal stimulation for Parkinson's disease affects neither memory nor executive functions: a consecutive series of 62 patients. Ann Neurol (1999) 1.57
Effect on mood of subthalamic DBS for Parkinson's disease: a consecutive series of 24 patients. Neurology (2002) 1.53
Comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation. Neurology (1999) 1.48
Acute psychotropic effects of bilateral subthalamic nucleus stimulation and levodopa in Parkinson's disease. Mov Disord (2003) 1.43
Neuropsychological outcome of GPi pallidotomy and GPi or STN deep brain stimulation in Parkinson's disease. Brain Cogn (2000) 1.35
Depression leading to attempted suicide after bilateral subthalamic nucleus stimulation for Parkinson's disease. Mov Disord (2002) 1.32
Subthalamic nucleus stimulation restores glucose metabolism in associative and limbic cortices and in cerebellum: evidence from a FDG-PET study in advanced Parkinson's disease. J Cereb Blood Flow Metab (2004) 1.28
Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov Disord (2002) 1.28
Neuropsychiatry of the basal ganglia. J Neurol Neurosurg Psychiatry (2002) 1.28
Mirthful laughter induced by subthalamic nucleus stimulation. Mov Disord (2001) 1.27
Aggressive behavior induced by intraoperative stimulation in the triangle of Sano. Neurology (2002) 1.27
Subthalamic nucleus stimulation affects striato-anterior cingulate cortex circuit in a response conflict task: a PET study. Brain (2002) 1.20
Manic episode with psychotic symptoms induced by subthalamic nucleus stimulation in a patient with Parkinson's disease. Mov Disord (2003) 1.20
Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: a functional MRI case study. Mov Disord (2003) 1.19
Subthalamic nucleus stimulation in Parkinson's disease: clinical evaluation of 18 patients. J Neurol (2002) 1.16
Subthalamic stimulation in Parkinson disease: a multidisciplinary approach. Arch Neurol (2000) 1.15
Influence of chronic bilateral stimulation of the subthalamic nucleus on cognitive function in Parkinson's disease. J Neurol (2001) 1.15
Compulsions, Parkinson's disease, and stimulation. Lancet (2002) 1.15
Long-term follow up of subthalamic nucleus stimulation in Parkinson's disease. Neurology (2002) 1.13
Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations. Mov Disord (2002) 1.11
Neuropsychological sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a critical review. Neuropsychol Rev (2002) 1.10
Deep brain stimulation of the subthalamic nucleus: clinical effectiveness and safety. Neurology (2001) 1.07
Mood changes with deep brain stimulation of STN and GPi: results of a pilot study. J Neurol Neurosurg Psychiatry (2003) 1.05
Bilateral subthalamic nucleus stimulation and quality of life in advanced Parkinson's disease. Mov Disord (2002) 1.04
Treatment results: Parkinson's disease. Mov Disord (2002) 1.04
Cognitive and behavioural effects of chronic stimulation of the subthalamic nucleus in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry (2003) 1.03
Results of chronic subthalamic nucleus stimulation for Parkinson's disease: a 1-year follow-up study. Surg Neurol (2002) 1.01
Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: comparison of pre- and postoperative neuropsychological evaluation. J Neurol Sci (2001) 0.99
Bilateral subthalamic nucleus stimulation improves health-related quality of life in PD. Neurology (2002) 0.98
Neuropsychological functioning following bilateral subthalamic nucleus stimulation in Parkinson's disease. Arch Clin Neuropsychol (2004) 0.95
Pseudobulbar crying induced by stimulation in the region of the subthalamic nucleus. J Neurol Neurosurg Psychiatry (2004) 0.94
Chronic inhibition of the subthalamic nucleus in Parkinson's disease. J Neurol Sci (2004) 0.94
Effect of motor improvement on quality of life following subthalamic stimulation is mediated by changes in depressive symptomatology. Stereotact Funct Neurosurg (2003) 0.93
Explosive-aggressive behavior related to bilateral subthalamic stimulation. Parkinsonism Relat Disord (2004) 0.93
Visual hallucinations induced by deep brain stimulation in Parkinson's disease. Clin Neuropharmacol (2001) 0.87
Deep brain stimulation of the subthalamic nucleus: effectiveness in advanced Parkinson's disease patients previously reliant on apomorphine. J Neurol Neurosurg Psychiatry (2003) 0.86
Apomorphine test: a predictor for motor responsiveness to deep brain stimulation of the subthalamic nucleus. J Neurol (1999) 0.81
Dopamine transporter binding in Gilles de la Tourette syndrome. J Neurol (2000) 1.79
No tissue damage by chronic deep brain stimulation in Parkinson's disease. Ann Neurol (2000) 1.49
Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. J Clin Endocrinol Metab (1997) 1.44
Initial experience with technetium-99m HM-PAO brain SPECT. J Nucl Med (1987) 1.30
Electromagnetic compatibility of electronic implants--review of the literature. Wien Klin Wochenschr (2001) 1.30
Fatal familial insomnia: a new Austrian family. Brain (1999) 1.24
A positron emission tomographic study of subthalamic nucleus stimulation in Parkinson disease: enhanced movement-related activity of motor-association cortex and decreased motor cortex resting activity. Arch Neurol (1999) 1.23
Multicentre European study of thalamic stimulation in essential tremor: a six year follow up. J Neurol Neurosurg Psychiatry (2003) 1.23
Twenty-four hour cortisol release profiles in patients with Alzheimer's and Parkinson's disease compared to normal controls: ultradian secretory pulsatility and diurnal variation. Neurobiol Aging (1997) 1.22
With aging in humans the activity of the hypothalamus-pituitary-adrenal system increases and its diurnal amplitude flattens. Life Sci (1997) 1.22
Multicentre European study of thalamic stimulation for parkinsonian tremor: a 6 year follow-up. J Neurol Neurosurg Psychiatry (2007) 1.11
Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging. J Nucl Med (2000) 1.07
Imaging the pre- and postsynaptic side of striatal dopaminergic synapses in idiopathic cervical dystonia: a SPECT study using [123I] epidepride and [123I] beta-CIT. Mov Disord (1998) 1.07
[123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm (Vienna) (1998) 1.07
[123I] beta-CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa. Biol Psychiatry (2001) 1.05
No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism. Biol Psychiatry (2001) 0.99
[123I]beta-CIT SPECT in multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration. Mov Disord (2000) 0.98
The activity of the sympathetic nervous system following severe head injury. Intensive Care Med (1980) 0.97
Differential modulation of subcortical target and cortex during deep brain stimulation. Neuroimage (2003) 0.95
Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology (1997) 0.95
Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. J Nucl Med (1997) 0.94
Treatment of severe tardive dystonia with pallidal deep brain stimulation. Neurology (2005) 0.93
Adult coeliac disease and brainstem encephalitis. J Neurol Neurosurg Psychiatry (1988) 0.92
[123I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biol Psychiatry (2000) 0.91
[Evaluating the quality of life before and after implantation of a total hip endoprosthesis]. Z Orthop Ihre Grenzgeb (1999) 0.88
Increased diurnal plasma concentrations of dehydroepiandrosterone in depressed patients. J Clin Endocrinol Metab (1998) 0.87
Nicotinamide adenine dinucleotide (NADH)--a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Acta Neurol Scand Suppl (1993) 0.87
Visual hallucinations induced by deep brain stimulation in Parkinson's disease. Clin Neuropharmacol (2001) 0.87
beta-CIT SPECT demonstrates blockade of 5HT-uptake sites by citalopram in the human brain in vivo. J Neural Transm Gen Sect (1995) 0.86
Training of affect recognition (TAR) in schizophrenia--impact on functional outcome. Schizophr Res (2012) 0.86
Prognostic factors in the treatment of cerebellar haemorrhage. Acta Neurochir (Wien) (1994) 0.86
Neurochemical aspects of the Rett syndrome. Brain Dev (1985) 0.85
Quantification of regional cerebral blood flow with IMP-SPECT. Reproducibility and clinical relevance of flow values. Stroke (1989) 0.84
Effect of calculation stress on hemodynamics and plasma catecholamines before and after beta-blockade with propranolol (Inderal) and mepindolol sulfate (Corindolan). Eur J Clin Pharmacol (1979) 0.84
Imaging of cerebral blood flow with technetium-99m-HMPAO and technetium-99m-ECD: a comparison. J Nucl Med (1998) 0.84
Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine. Int Clin Psychopharmacol (2000) 0.83
Reduced concentrations and increased metabolism of biogenic amines in a single case of Rett-syndrome: a postmortem brain study. J Neural Transm (1987) 0.83
A medial to lateral shift in pre-movement cortical activity in hemi-Parkinson's disease. Clin Neurophysiol (2001) 0.83
Deep brain stimulation of the subthalamic nucleus for control of extrapyramidal features in advanced idiopathic parkinson's disease: one year follow-up. J Neural Transm (Vienna) (1999) 0.83
Changes in handwriting resulting from bilateral high-frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov Disord (1999) 0.83
Thalamic stimulation for essential tremor activates motor and deactivates vestibular cortex. Neurology (2001) 0.83
Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics. Lancet (1992) 0.83
Superselective indocyanine green angiography for selective revascularization in the management of peripheral cerebral aneurysms. AJNR Am J Neuroradiol (2011) 0.82
Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients. Psychopharmacology (Berl) (1997) 0.81
The Austrian FFI cases. Brain Pathol (1998) 0.81
Apomorphine test: a predictor for motor responsiveness to deep brain stimulation of the subthalamic nucleus. J Neurol (1999) 0.81
The impact of social exclusion vs. inclusion on subjective and hormonal reactions in females and males. Psychoneuroendocrinology (2013) 0.81
Radiochemical synthesis of [18F]fluororaclopride. Int J Rad Appl Instrum A (1989) 0.81
[A comparative study on the effect of halothan-N2O-anaesthesia and neuroleptanalgesia on plasma catecholamines during the intra- and postoperative period (author's transl)]. Anaesthesist (1979) 0.81
Ruptured carotid artery aneurysms of the ophthalmic (C6) segment: clinical and angiographic long term follow-up of a multidisciplinary management strategy. J Neurol Neurosurg Psychiatry (2009) 0.80
Pulse-dosing and conventional application of doxepin: effects on psychopathology and hypothalamus-pituitary-adrenal (HPA) system. J Clin Psychopharmacol (1997) 0.80
Ventral intermediate thalamic stimulation in complex tremor syndromes. Stereotact Funct Neurosurg (2008) 0.80
Corticosteroid-binding globulin is not decreased in depressed patients. Psychoneuroendocrinology (1996) 0.80
Seasonal variation of availability of serotonin transporter binding sites in healthy female subjects as measured by [123I]-2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane and single photon emission computed tomography. Biol Psychiatry (2000) 0.80
New rapid analysis method demonstrates differences in 6-[18F] fluoro-L-dopa plasma input curves with and without carbidopa and in hemi-MPTP lesioned monkeys. Int J Rad Appl Instrum A (1991) 0.79
Kinematic evaluation in Parkinson's disease using a hand-held position transducer and computerized signal analysis. Acta Neurochir (Wien) (2005) 0.79
Olfactory functions in Parkinson's disease and Alzheimer's disease. Chem Senses (1997) 0.79
IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol. Psychopharmacology (Berl) (1997) 0.79
In vivo visualization of serotonin transporters in the human brain during fluoxetine treatment. Eur Neuropsychopharmacol (1999) 0.79
Blockade of in vivo binding of 125I-labeled 3-iodobenzamide (IBZM) to dopamine receptors by D2 antagonist and agonist. Brain Res (1988) 0.79
[Intraventricular morphine administration as a treatment possibility for patients with intractable pain]. Wien Klin Wochenschr (1996) 0.78
NOAC and intracerebral bleeding--presentation of four cases and review of the literature. Bull Soc Sci Med Grand Duche Luxemb (2014) 0.78
Bilateral subthalamic nucleus stimulation does not improve prolonged P300 latencies in Parkinson's disease. J Neurol (2001) 0.78
Influence of aortic blood flow velocity on changes of middle cerebral artery blood flow velocity during isoflurane and sevoflurane anaesthesia. Eur J Anaesthesiol (2001) 0.78
Iodine-123-IBZM-SPECT: studies in 15 patients with pituitary tumors. J Neural Transm Gen Sect (1994) 0.78
Amantadine in Parkinson's disease: lymphocyte subsets and IL-2 secreting T cell precursor frequencies. Exp Gerontol (2001) 0.78
Technetium-99m-HMPAO SPECT imaging of cerebral blood flow during REM sleep in narcoleptics. J Nucl Med (1995) 0.78
Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol - a 123I-IBZM SPECT study. Psychopharmacology (Berl) (1998) 0.78
SPECT imaging of dopamine receptors with [123I]epidepride: characterization of uptake in the human brain. J Neural Transm Gen Sect (1995) 0.78
Impaired olfactory function in Parkinson's disease. Lancet (1995) 0.77
[123I]beta-CIT single-photon emission tomography in DOPA-responsive dystonia. Mov Disord (1997) 0.77
Acute porphyric neuropathy during pregnancy--effect of haematin therapy. Eur Neurol (1998) 0.77
Beta-CIT SPECT demonstrates reduced availability of serotonin transporters in patients with Fatal Familial Insomnia. J Neural Transm (Vienna) (2002) 0.77
Dynamic SPECT in two healthy volunteers to determine the optimal time for in vivo D2 dopamine receptor imaging with 123I-IBZM using the rotating gamma camera. Nucl Med Commun (1991) 0.77
In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology (Berl) (1999) 0.77
Does deep brain stimulation of the nucleus ventralis intermedius affect postural control and locomotion in Parkinson's disease? Mov Disord (1999) 0.77
Endurance training and its effect upon the activity of the GH-IGFs system in the elderly. Int J Sports Med (1998) 0.77
Polyacryl prosthesis for cranioplasty--their production in silicon rubber casts. Acta Neurochir (Wien) (1985) 0.76
GABA-activated chloride currents of postnatal mouse retinal ganglion cells are blocked by acetylcholine and acetylcarnitine: how specific are ion channels in immature neurons? Eur J Neurosci (1994) 0.76
[Huntington chorea: (CAG)n repeats on gene IT 15 in Austria]. Wien Klin Wochenschr (1994) 0.76
Dopamine D2 receptor binding is reduced in Wilson's disease: correlation of neurological deficits with striatal 123I-iodobenzamide binding. J Neural Transm (Vienna) (1996) 0.76
Dopamine D2 receptor blockade and antimigraine action of flunarizine. Cephalalgia (1994) 0.76
Multimodality treatment of malignant gliomas. Comparison of several adjuvant approaches. Zentralbl Neurochir (1981) 0.76
The combined dexamethasone/corticotropin-releasing hormone stimulation test is more closely associated with features of diurnal activity of the hypothalamo-pituitary-adrenocortical system than the dexamethasone suppression test. Biol Psychiatry (1998) 0.76
[Current biochemical hypotheses of endogenous depression]. Wien Klin Wochenschr (1985) 0.76
Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease. J Nucl Med (1997) 0.76
Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine. Psychopharmacology (Berl) (1997) 0.76
[Quality of life five years after total or partial knee arthroplasty]. Z Orthop Ihre Grenzgeb (2003) 0.76
Changes in attention with hypo- and hyperglycaemia in children with insulin dependent diabetes mellitus. Eur J Pediatr (1998) 0.76
The involvement of the sympathetic nervous system in tetanus. Klin Wochenschr (1979) 0.75
Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT. J Nucl Med (1996) 0.75
IBZM-SPECT imaging of dopamine D(2) receptors with typical and atypical antipsychotics. Eur Psychiatry (1998) 0.75
Vascular dementia. Neurology (1992) 0.75
[Stereotactic brain biopsy in AIDS patients: a necessary patient-oriented and cost-effective diagnostic measure?]. Acta Med Austriaca (1998) 0.75
Nortriptyline pulse loading in depressed patients. J Clin Psychopharmacol (1998) 0.75